Should I buy or sell Eagle Pharmaceuticals stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Eagle Pharmaceuticals in the last year. There are currently 1 sell rating for the stock. The consensus among Wall Street research analysts is that investors should "sell" EGRX shares. View EGRX analyst ratings or view top-rated stocks .

What is Eagle Pharmaceuticals' stock price target for 2024?

1 Wall Street research analysts have issued 1-year target prices for Eagle Pharmaceuticals' shares. Their EGRX share price targets range from $17.00 to $17.00. On average, they anticipate the company's stock price to reach $17.00 in the next twelve months. This suggests a possible upside of 226.9% from the stock's current price. View analysts price targets for EGRX or view top-rated stocks among Wall Street analysts .

How have EGRX shares performed in 2024?

Eagle Pharmaceuticals' stock was trading at $5.23 at the start of the year. Since then, EGRX shares have decreased by 0.6% and is now trading at $5.20. View the best growth stocks for 2024 here .

When is Eagle Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our EGRX earnings forecast .

How were Eagle Pharmaceuticals' earnings last quarter?

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) posted its quarterly earnings data on Tuesday, November, 9th. The specialty pharmaceutical company reported $0.56 earnings per share for the quarter, beating analysts' consensus estimates of ($0.44) by $1.00. The specialty pharmaceutical company earned $39.85 million during the quarter, compared to the consensus estimate of $46.70 million. During the same period in the prior year, the business posted $0.51 earnings per share.

What other stocks do shareholders of Eagle Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eagle Pharmaceuticals investors own include Gilead Sciences (GILD) , Exelixis (EXEL) , Teekay Tankers (TNK) , AbbVie (ABBV) , Intercept Pharmaceuticals (ICPT) , Radius Recycling (RDUS) , bluebird bio (BLUE) , Clovis Oncology (CLVS) , GW Pharmaceuticals (GWPH) and Incyte (INCY) .

Who are Eagle Pharmaceuticals' major shareholders?

Eagle Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Los Angeles Capital Management LLC (1.48%) and DGS Capital Management LLC (0.48%). Insiders that own company stock include Richard A Edlin and Scott Tarriff. View institutional ownership trends .

How do I buy shares of Eagle Pharmaceuticals?

Shares of EGRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:EGRX

Eagle Pharmaceuticals (EGRX) Stock Price, News & Analysis

→ Forget Nvidia, buy this A.I. Stock Now (From InvestorPlace) (Ad)

Free EGRX Stock Alerts

$5.20

+0.61 (+13.29%)

(As of 04/15/2024 ET)

Compare

Today's Range: $4.28
▼
$5.26
50-Day Range: $4.50
▼
$6.51
52-Week Range: $4.10
▼
$30.43

Volume: 379,131 shs
Average Volume: 226,095 shs
Market Capitalization: $67.55 million

P/E Ratio: 4.41
Dividend Yield: N/A
Price Target: $17.00

Get Eagle Pharmaceuticals alerts:

Eagle Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Sell
1.00 Rating Score
Upside/Downside: 226.9% Upside
$17.00 Price Target
Short Interest: Bearish
10.59% of Float Sold Short
Dividend Strength: N/A
Sustainability: -2.29
Upright™ Environmental Score
News Sentiment: 0.27
Based on 7 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.69 out of 5 stars

Medical Sector

244th out of 929 stocks

Pharmaceutical Preparations Industry

104th out of 422 stocks

2.5

Analyst's Opinion

Consensus Rating
Eagle Pharmaceuticals has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no buy ratings, no hold ratings, and 1 sell rating.
Amount of Analyst Coverage
Eagle Pharmaceuticals has received no research coverage in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
10.59% of the float of Eagle Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Eagle Pharmaceuticals has a short interest ratio ("days to cover") of 5.3.
Change versus previous month
Short interest in Eagle Pharmaceuticals has recently increased by 4.31%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Eagle Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Eagle Pharmaceuticals does not have a long track record of dividend growth.

3.9

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Eagle Pharmaceuticals has received a 53.97% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Bendamustine", "Dantrolene", and "Pemetrexed" products. See details.
Environmental Sustainability
The Environmental Impact score for Eagle Pharmaceuticals is -2.29.

1.8

News and Social Media Coverage

News Sentiment
Eagle Pharmaceuticals has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 7 news articles for Eagle Pharmaceuticals this week, compared to 2 articles on an average week.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Eagle Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
28.90% of the stock of Eagle Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
85.36% of the stock of Eagle Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Eagle Pharmaceuticals is 4.41, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 142.24.
Price to Earnings Ratio vs. Sector
The P/E ratio of Eagle Pharmaceuticals is 4.41, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 249.13.
Price to Book Value per Share Ratio
Eagle Pharmaceuticals has a P/B Ratio of 0.29. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

Trump’s “Tax Free” Retirement Strategy

Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.

Protect your retirement savings from the inevitable devaluation of the dollar…

About Eagle Pharmaceuticals Stock (NASDAQ:EGRX)

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.

EGRX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

EGRX Stock News Headlines

April 15, 2024 | globenewswire.com

Eagle Pharmaceuticals to Present Additional Data from Phase III Trial Demonstrating Sustained Response of Amisulpride for the Rescue Treatment of Postoperative Nausea and Vomiting (PONV) at the Upcoming ASPAN 2024 National Conference in Orlando, Florida

April 14, 2024 | investing.com

Eagle Pharmaceuticals faces potential Nasdaq delisting

April 16, 2024 | Porter & Company (Ad)

The #1 Investment of the Decade…

Sam Altman, the CEO of OpenAI, has invested $375 million into a breakthrough technology, that legendary financial analyst Porter Stansberry believes… …could be the number-one investment of the decade.

April 13, 2024 | msn.com

Stocks Slightly Higher as US Mar PPI Climbs Less Than Expected

April 13, 2024 | msn.com

Stocks Mixed as Bond Yields Climb

April 12, 2024 | finance.yahoo.com

Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Annual Report on Form 10-K

April 12, 2024 | globenewswire.com

Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Annual Report on Form 10-K

February 29, 2024 | msn.com

Eagle Pharmaceuticals to cut 36% of workforce

April 16, 2024 | Porter & Company (Ad)

The #1 Investment of the Decade…

February 22, 2024 | benzinga.com

Eagle Pharmaceuticals Stock (NASDAQ:EGRX), Short Interest Report

February 22, 2024 | benzinga.com

Eagle Pharmaceuticals Stock (NASDAQ:EGRX) Dividends: History, Yield and Dates

February 9, 2024 | prnewswire.com

EAGLE PHARMACEUTICALS SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Eagle Pharmaceuticals To Contact Him Directly To Discuss Their Options

February 8, 2024 | stockhouse.com

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Eagle Pharmaceuticals, Inc. (EGRX)

February 8, 2024 | markets.businessinsider.com

Levi & Korsinsky Notifies Shareholders of Eagle Pharmaceuticals, Inc.(EGRX) of a Class Action Lawsuit and an Upcoming Deadline

February 8, 2024 | markets.businessinsider.com

Shareholders that lost money on Eagle Pharmaceuticals, Inc.(EGRX) should contact Levi & Korsinsky about pending Class Action - EGRX

February 7, 2024 | markets.businessinsider.com

Class Action Filed Against Eagle Pharmaceuticals, Inc. (EGRX) Seeking Recovery for Investors - Contact Levi & Korsinsky

February 6, 2024 | stockhouse.com

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Eagle Pharmaceuticals, Inc.(EGRX) Investors of a Class Action Lawsuit and Upcoming Deadline

February 2, 2024 | stockhouse.com

7-DAY DEADLINE ALERT: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

February 2, 2024 | barrons.com

EGRX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Eagle Pharmaceuticals, Inc. Shareholders to Contact the Firm!

February 1, 2024 | stockhouse.com

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

February 1, 2024 | markets.businessinsider.com

EGRX 9-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Eagle Pharmaceuticals (EGRX) Investors with Substantial Losses to Contact Firm Before Feb. 9th Deadline in Securities...

January 31, 2024 | stockhouse.com

INVESTOR ALERT: Levi & Korsinsky Notifies Eagle Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - EGRX

January 31, 2024 | barrons.com

INVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

January 30, 2024 | stockhouse.com

INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Eagle Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

January 30, 2024 | stockhouse.com

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Eagle Pharmaceuticals, Inc. (EGRX) Investors of a Class Action Lawsuit and Upcoming Deadline

January 28, 2024 | stockhouse.com

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Eagle Pharmaceuticals, Inc. - EGRX

January 28, 2024 | markets.businessinsider.com

Eagle Pharmaceuticals (EGRX) Tells SEC It Improperly Accounted for Past Two Quarters and Defaults on Lender Agreement - Hagens Berman

See More Headlines

Receive EGRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eagle Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/09/2021
Today: 4/15/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:EGRX
CUSIP: N/A
CIK: 827871
Web: www.eagleus.com
Phone: (201) 326-5300
Fax: N/A
Employees: 134
Year Founded: 2007

Price Target and Rating

Average Stock Price Target: $17.00
High Stock Price Target: $17.00
Low Stock Price Target: $17.00
Potential Upside/Downside: +226.9%
Consensus Rating: Sell
Rating Score (0-4): 1.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: 4.41
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: $316.61 million
Price / Sales: 0.21
Cash Flow: $4.30 per share
Price / Cash Flow: 1.21
Book Value: $17.94 per share
Price / Book: 0.29

Miscellaneous

Outstanding Shares: 12,990,000
Free Float: 9,234,000
Market Cap: $67.55 million
Optionable: Optionable
Beta: 0.41

Social Links

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Mr. Michael Graves (Age 61)
Interim Principal Executive Officer & Executive Chairman of the Board
Comp: $160k
Mr. Steven B. Ratoff (Age 81)
Interim CFO, Principal Accounting Officer & Director
Comp: $100k
Mr. Daniel O'Connor (Age 44)
Executive VP, Chief Strategy Officer & Head of Corporate Development
Dr. Valentin R. Curt M.D.
Senior Vice President of Clinical Drug Development
Dr. Gaozhong Zhu Ph.D.
Senior Vice President of Pharmaceutical Development
Ms. Debra M. Hussain
Senior VP & Head of Commercial
Mr. Reed McClung
Executive Vice President of Oncology Business Development

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

EGRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Eagle Pharmaceuticals stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Eagle Pharmaceuticals in the last year. There are currently 1 sell rating for the stock. The consensus among Wall Street research analysts is that investors should "sell" EGRX shares.
View EGRX analyst ratings or view top-rated stocks.
What is Eagle Pharmaceuticals' stock price target for 2024?: 1 Wall Street research analysts have issued 1-year target prices for Eagle Pharmaceuticals' shares. Their EGRX share price targets range from $17.00 to $17.00. On average, they anticipate the company's stock price to reach $17.00 in the next twelve months. This suggests a possible upside of 226.9% from the stock's current price.
View analysts price targets for EGRX or view top-rated stocks among Wall Street analysts.
How have EGRX shares performed in 2024?: Eagle Pharmaceuticals' stock was trading at $5.23 at the start of the year. Since then, EGRX shares have decreased by 0.6% and is now trading at $5.20.
View the best growth stocks for 2024 here.
When is Eagle Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our EGRX earnings forecast.

How were Eagle Pharmaceuticals' earnings last quarter?: Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) posted its quarterly earnings data on Tuesday, November, 9th. The specialty pharmaceutical company reported $0.56 earnings per share for the quarter, beating analysts' consensus estimates of ($0.44) by $1.00. The specialty pharmaceutical company earned $39.85 million during the quarter, compared to the consensus estimate of $46.70 million. During the same period in the prior year, the business posted $0.51 earnings per share.
What other stocks do shareholders of Eagle Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Eagle Pharmaceuticals investors own include Gilead Sciences (GILD), Exelixis (EXEL), Teekay Tankers (TNK), AbbVie (ABBV), Intercept Pharmaceuticals (ICPT), Radius Recycling (RDUS), bluebird bio (BLUE), Clovis Oncology (CLVS), GW Pharmaceuticals (GWPH) and Incyte (INCY).
Who are Eagle Pharmaceuticals' major shareholders?: Eagle Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Los Angeles Capital Management LLC (1.48%) and DGS Capital Management LLC (0.48%). Insiders that own company stock include Richard A Edlin and Scott Tarriff.
View institutional ownership trends.
How do I buy shares of Eagle Pharmaceuticals?: Shares of EGRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:EGRX) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial